

PRESS CLIPPING SHEET

PUBLICATION:	Egyptian Gazette
DATE:	6-September-2015
COUNTRY:	Egypt
CIRCULATION:	60,000
TITLE :	AbbVie's QUREVO Receives Approval by the Egyptian Ministry of Health for HCV Treatment
PAGE:	03
ARTICLE TYPE:	Health Corporate news
REPORTER:	Staff Report

AbbVie's QUREVO receives approval by the Egyptian Ministry of Health for HCV treatment

ABBVIE, a global research-based biopharmaceutical company, announced that the Egyptian Ministry of Health (MOH) has approved QUREVO (ombitasvir/paritaprevir/ritonavir tablets) in combination with ribavirin (RBV), an all-oral, interferon-free treatment for patients living with chronic hepatitis C virus (HCV) infection.

Treating HCV is complex as the virus mutates and replicates rapidly. QUREVO combines two direct-acting antivirals to attack the virus at two separate stages of its replication process. The approval of QUREVO is the result of the MOH's efforts to approve medicines that will help improve health conditions for Egyptians and protect them from chronic diseases like hepatitis HCV.

Egypt has the highest prevalence of HCV worldwide, with a high per cent

of the country's population living with the disease. Of those, Egyptian patients living with HCV, it is estimated that 90 per cent are infected with genotype 4 (GT4). Every year, an estimated 40,000 Egyptians die as a result of HCV. The MOH has made hepatitis C a national health priority and AbbVie is collaborating with government officials to help identify and address the diverse challenges and unmet needs across Egypt.

"We are proud to provide QUREVO as a new, breakthrough treatment that offers high cure rates for people living with HCV," said Amjad Laimoun, General Manager, AbbVie Egypt. "The approval of QUREVO reflects the shared commitment of AbbVie and the Egyptian Government to work together and find sustainable solutions to urgently reduce the burden of HCV in Egypt."